Breast Cancer Clinical Trial
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
Summary
The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal therapy.
Eligibility Criteria
Inclusion Criteria:
Written informed consent
Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease
One or more evaluable lesions
Exclusion Criteria:
Prior hormonal therapy with fulvestrant
More than one course of prior systemic cytotoxic chemotherapy for metastatic breast cancer
Prior biologic therapy for ABC including Anti-VEGF agents
Radiation therapy within 4 weeks prior to provision of consent
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Burbank California, , United States
Los Angeles California, , United States
Palm Springs California, , United States
Boca Raton Florida, , United States
Honolulu Hawaii, , United States
New York New York, , United States
Fitzroy , , Australia
Parkville , , Australia
Perth , , Australia
Waratah , , Australia
Belo Horizonte , , Brazil
Curitiba , , Brazil
Fortaleza , , Brazil
Porto Alegre , , Brazil
Santro Andre , , Brazil
São Paulo , , Brazil
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.